[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:diffuse-large-b-cell-lymphoma":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":311,"states":346},"Diffuse Large B-Cell Lymphoma",175,147,[8,16,23,29,35,42,48,54,61,68,74,80,86,91,97,103,109,115,121,127,133,139,145,151,157,163,169,175,180,186,193,199,205,211,216,222,227,233,239,245,251,257,263,269,275,281,287,293,299,305],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT06249191","Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma",[12],"Phase 1\u002FPhase 2","RECRUITING","2026-08-26T02:18:09.641312Z","2026-07-19T19:36:05.128454Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT06528301","A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed\u002FRefractory CD19+ B-cell Malignancies",[20],"Phase 1","2026-08-26T02:15:52.238965Z","2026-07-05T05:32:16.758292Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":27,"content_modified":28},"NCT06447376","Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to Epcoritamab",[20],"2026-08-26T02:17:18.747857Z","2026-07-05T05:32:16.755616Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":33,"content_modified":34},"NCT06898905","Hyperfractionated Dual Equivalent Fractionated Radiation Therapy",[],"2026-08-26T02:16:01.079019Z","2026-07-05T05:32:16.700783Z",{"nct_id":36,"title":37,"phases":38,"status":13,"updated_at":40,"content_modified":41},"NCT06091865","A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma",[39],"Phase 3","2026-08-26T02:15:41.377360Z","2026-05-29T15:36:40.167745Z",{"nct_id":43,"title":44,"phases":45,"status":13,"updated_at":46,"content_modified":47},"NCT06768905","IOMAB-CAR-T Followed by CAR-T Cell Therapy in R\u002FR DLBCL",[12],"2026-08-26T02:19:16.454910Z","2026-05-05T02:43:29.506243Z",{"nct_id":49,"title":50,"phases":51,"status":13,"updated_at":52,"content_modified":53},"NCT05487170","A Study of RNK05047 in Subjects With Advanced Solid Tumors\u002FDiffuse Large B-cell Lymphoma (CHAMP-1)",[12],"2026-08-26T02:17:51.502023Z","2026-05-05T02:43:29.296319Z",{"nct_id":55,"title":56,"phases":57,"status":13,"updated_at":59,"content_modified":60},"NCT06594939","Mosunetuzumab and Polatuzumab Vedotin With Split-Dose CHP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma",[58],"Phase 2","2026-08-26T02:18:13.438956Z","2026-05-05T02:43:29.130167Z",{"nct_id":62,"title":63,"phases":64,"status":13,"updated_at":66,"content_modified":67},"NCT05800405","Evaluation of Bridging Radiation Therapy Before CAR T-Cell Infusion for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma",[65],"Early Phase 1","2026-08-26T02:17:16.980188Z","2026-05-05T02:43:29.075956Z",{"nct_id":69,"title":70,"phases":71,"status":13,"updated_at":72,"content_modified":73},"NCT06624085","A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma",[20],"2026-08-03T03:20:26.944531Z","2026-05-05T02:43:28.955730Z",{"nct_id":75,"title":76,"phases":77,"status":13,"updated_at":78,"content_modified":79},"NCT06846463","Zanubrutinib in Patients With DLBCL and MYD88 or NOTCH1 Mutation or CD5+",[58],"2026-08-26T02:19:13.549512Z","2026-05-05T02:43:28.810232Z",{"nct_id":81,"title":82,"phases":83,"status":13,"updated_at":84,"content_modified":85},"NCT04002947","Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma",[58],"2026-08-26T02:17:04.346841Z","2026-05-05T02:43:28.535260Z",{"nct_id":87,"title":88,"phases":89,"status":13,"updated_at":27,"content_modified":90},"NCT06789159","A Phase Ib Study of VK-2019 in Patients With Relapsed or Refractory EBV+ Diffuse Large B-cell Lymphomas (DLBCL)",[20],"2026-05-05T02:43:28.339016Z",{"nct_id":92,"title":93,"phases":94,"status":13,"updated_at":95,"content_modified":96},"NCT05952024","Study of Acalabrutinib and Rituximab in Untreated Elderly and\u002For Frail Patients With DLBCL",[58],"2026-08-26T02:15:59.318403Z","2026-05-05T02:43:28.220544Z",{"nct_id":98,"title":99,"phases":100,"status":13,"updated_at":101,"content_modified":102},"NCT06854159","Odronextamab for the Treatment of Relapsed and Refractory Diffuse Large B-cell Lymphoma Before and After Chimeric Antigen Receptor T-cell Therapy",[58],"2026-08-26T02:15:33.331531Z","2026-05-05T02:43:27.997454Z",{"nct_id":104,"title":105,"phases":106,"status":13,"updated_at":107,"content_modified":108},"NCT07528352","External Beam Radiotherapy Followed by Bispecific Antibody Therapy for Relapsed\u002FRefractory DLBCL",[20],"2026-08-26T02:17:01.714035Z","2026-05-05T02:43:27.930526Z",{"nct_id":110,"title":111,"phases":112,"status":13,"updated_at":113,"content_modified":114},"NCT04139304","A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma",[65],"2026-08-26T02:19:05.360997Z","2026-05-05T02:43:27.918186Z",{"nct_id":116,"title":117,"phases":118,"status":13,"updated_at":119,"content_modified":120},"NCT04920617","DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed\u002FRefractory Diffuse Large B-Cell Lymphoma",[58],"2026-08-26T02:18:08.005333Z","2026-05-05T02:43:27.857898Z",{"nct_id":122,"title":123,"phases":124,"status":13,"updated_at":125,"content_modified":126},"NCT06687772","CNS-Relapse Prevention in High-Risk Diffuse Large B-cell Lymphoma With Thiotepa-based Autologous Stem Cell Transplant",[58],"2026-08-26T02:15:40.343619Z","2026-05-05T02:43:27.846837Z",{"nct_id":128,"title":129,"phases":130,"status":13,"updated_at":131,"content_modified":132},"NCT06104592","Single-Arm Comprehensive Ablative Bridging Irradiation I Prior to CD19 CAR-T In High-Risk R\u002FR LBCL",[58],"2026-08-26T02:17:05.172421Z","2026-05-05T02:43:27.667369Z",{"nct_id":134,"title":135,"phases":136,"status":13,"updated_at":137,"content_modified":138},"NCT07478848","Radiation, Oral Vancomycin, and CAR-T for B-Cell Lymphomas",[20],"2026-08-26T02:18:57.189473Z","2026-05-05T02:43:27.504670Z",{"nct_id":140,"title":141,"phases":142,"status":13,"updated_at":143,"content_modified":144},"NCT06890884","A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011\u002FwaveLINE-011)",[58],"2026-08-26T02:16:38.897933Z","2026-05-05T02:43:27.404788Z",{"nct_id":146,"title":147,"phases":148,"status":13,"updated_at":149,"content_modified":150},"NCT06607549","Loncastuximab Tesirine and Rituximab Following Stereotactic Radiosurgery in Patients With Central Nervous System Lymphomas (SOLAR)",[20],"2026-08-26T02:18:42.501841Z","2026-05-05T02:43:27.286682Z",{"nct_id":152,"title":153,"phases":154,"status":13,"updated_at":155,"content_modified":156},"NCT06045247","Phase 2 Trial of Epcoritamab in Combination With Rituximab-mini CVP for Older Unfit\u002FFrail Patients or Anthracycline-Ineligible Adult Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma",[58],"2026-08-26T02:16:57.705506Z","2026-05-05T02:43:27.172301Z",{"nct_id":158,"title":159,"phases":160,"status":13,"updated_at":161,"content_modified":162},"NCT05905328","Study of CTO1681 for the Prevention and Treatment of CRS in DLBCL Patients Receiving CAR T-Cell Therapy",[12],"2026-08-26T02:18:29.369233Z","2026-05-05T02:43:27.127247Z",{"nct_id":164,"title":165,"phases":166,"status":13,"updated_at":167,"content_modified":168},"NCT06717347","A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)",[39],"2026-08-26T02:17:06.985283Z","2026-05-05T02:43:27.058133Z",{"nct_id":170,"title":171,"phases":172,"status":13,"updated_at":173,"content_modified":174},"NCT05800366","A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma",[58],"2026-08-26T02:15:44.309045Z","2026-05-05T02:43:26.740303Z",{"nct_id":176,"title":177,"phases":178,"status":13,"updated_at":46,"content_modified":179},"NCT05757219","Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy",[58],"2026-05-05T02:43:26.678511Z",{"nct_id":181,"title":182,"phases":183,"status":13,"updated_at":184,"content_modified":185},"NCT05052528","Fludarabine and Cyclophosphamide With or Without Rituximab Before CD19 Chimeric Antigen Receptor T Cells for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma",[20],"2026-08-26T02:18:52.966503Z","2026-05-05T02:35:31.778323Z",{"nct_id":187,"title":188,"phases":189,"status":13,"updated_at":191,"content_modified":192},"NCT05139017","A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)",[190],"Phase 2\u002FPhase 3","2026-08-26T02:17:16.126291Z","2026-05-05T02:35:31.645602Z",{"nct_id":194,"title":195,"phases":196,"status":13,"updated_at":197,"content_modified":198},"NCT07316010","Phase 2 Trial of Lisocabtagene Maraleucel for Minimal Residual Disease in Patients With Large B-cell Lymphoma",[58],"2026-08-26T02:19:27.519777Z","2026-05-05T02:35:31.631978Z",{"nct_id":200,"title":201,"phases":202,"status":13,"updated_at":203,"content_modified":204},"NCT06977711","Loncastuximab and Roflumilast Added to R-CHOP (Lo-(Rituximab and Roflumilast) RR-CHOP) for Naïve High-Risk Diffuse Large B-cell Lymphoma (DLBCL)",[20],"2026-08-26T02:17:44.240289Z","2026-05-05T02:35:31.627346Z",{"nct_id":206,"title":207,"phases":208,"status":13,"updated_at":209,"content_modified":210},"NCT06806033","A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed\u002FRefractory Aggressive B-Cell Non-Hodgkin's Lymphoma",[58],"2026-08-26T02:15:56.561131Z","2026-05-05T02:35:31.607270Z",{"nct_id":212,"title":213,"phases":214,"status":13,"updated_at":14,"content_modified":215},"NCT05365659","IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas",[20],"2026-07-30T01:46:14.462340Z",{"nct_id":217,"title":218,"phases":219,"status":13,"updated_at":220,"content_modified":221},"NCT06863402","Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype",[58],"2026-08-26T02:15:54.846520Z","2026-07-24T01:27:14.890802Z",{"nct_id":223,"title":224,"phases":225,"status":13,"updated_at":101,"content_modified":226},"NCT05351593","Tafasitamab Plus Lenalidomide in Relapsed CNS Lymphoma",[12],"2026-07-19T19:36:05.117507Z",{"nct_id":228,"title":229,"phases":230,"status":13,"updated_at":231,"content_modified":232},"NCT04889716","CAR-T Followed by Bispecific Antibodies",[58],"2026-08-26T02:19:00.742020Z","2026-07-05T05:32:16.799310Z",{"nct_id":234,"title":235,"phases":236,"status":13,"updated_at":237,"content_modified":238},"NCT07226843","A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers",[20],"2026-08-26T02:15:58.452248Z","2026-07-05T05:32:16.666342Z",{"nct_id":240,"title":241,"phases":242,"status":13,"updated_at":243,"content_modified":244},"NCT06649812","Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and\u002For Refractory Aggressive B-cell Lymphoma",[58],"2026-08-26T02:16:17.877565Z","2026-06-16T05:54:07.922088Z",{"nct_id":246,"title":247,"phases":248,"status":13,"updated_at":249,"content_modified":250},"NCT06393738","A Study of ARV-393 in Relapsed\u002FRefractory Non-Hodgkin Lymphoma.",[20],"2026-08-26T02:17:36.611194Z","2026-05-05T02:43:29.734935Z",{"nct_id":252,"title":253,"phases":254,"status":13,"updated_at":255,"content_modified":256},"NCT05600686","Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell Lymphoma",[58],"2026-08-26T02:16:21.385056Z","2026-05-05T02:43:29.693214Z",{"nct_id":258,"title":259,"phases":260,"status":13,"updated_at":261,"content_modified":262},"NCT06828991","A Study to Evaluate the Impact of Mosunetuzumab Consolidation for Older Patients With Diffuse Large B-cell Lymphoma (DLBCL) Who Have Detectable Amounts of ctDNA (Circulating Tumor DNA) at the End of Treatment With Pola-R-mini-CHP",[58],"2026-08-26T02:17:35.666428Z","2026-05-05T02:43:29.283059Z",{"nct_id":264,"title":265,"phases":266,"status":13,"updated_at":267,"content_modified":268},"NCT05512390","A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R\u002FR) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)",[20],"2026-08-26T02:17:30.145302Z","2026-05-05T02:43:29.159145Z",{"nct_id":270,"title":271,"phases":272,"status":13,"updated_at":273,"content_modified":274},"NCT05272384","Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma",[20],"2026-08-26T02:18:41.390601Z","2026-05-05T02:43:29.137336Z",{"nct_id":276,"title":277,"phases":278,"status":13,"updated_at":279,"content_modified":280},"NCT05890352","Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment",[58],"2026-08-26T02:19:14.560989Z","2026-05-05T02:43:28.725480Z",{"nct_id":282,"title":283,"phases":284,"status":13,"updated_at":285,"content_modified":286},"NCT05256641","Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma",[12],"2026-08-26T02:19:19.975067Z","2026-05-05T02:43:28.530741Z",{"nct_id":288,"title":289,"phases":290,"status":13,"updated_at":291,"content_modified":292},"NCT06765317","A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma",[58],"2026-08-26T02:16:59.895916Z","2026-05-05T02:43:28.346447Z",{"nct_id":294,"title":295,"phases":296,"status":13,"updated_at":297,"content_modified":298},"NCT06500273","Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL",[58],"2026-08-26T02:17:19.710918Z","2026-05-05T02:43:28.207810Z",{"nct_id":300,"title":301,"phases":302,"status":13,"updated_at":303,"content_modified":304},"NCT03758989","A Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell Lymphoma",[58],"2026-08-26T02:16:50.548894Z","2026-05-05T02:43:28.176656Z",{"nct_id":306,"title":307,"phases":308,"status":13,"updated_at":309,"content_modified":310},"NCT06458439","Epcoritamab-CAR T Cells for Large B-cell Lymphomas",[58],"2026-08-26T02:17:54.420226Z","2026-05-05T02:43:28.016787Z",[312,316,320,324,327,331,335,339,343],{"biomarker":313,"count":314,"slug":315},"CD19 Gene",21,"cd19-gene",{"biomarker":317,"count":318,"slug":319},"MS4A1 Gene",18,"ms4a1-gene",{"biomarker":321,"count":322,"slug":323},"BCL2 Gene",13,"bcl2-gene",{"biomarker":325,"count":322,"slug":326},"MYC Gene","myc-gene",{"biomarker":328,"count":329,"slug":330},"BCL6 Gene",12,"bcl6-gene",{"biomarker":332,"count":333,"slug":334},"HIV Infection",5,"hiv-infection",{"biomarker":336,"count":337,"slug":338},"CD22 Gene",4,"cd22-gene",{"biomarker":340,"count":341,"slug":342},"MBD5 wt Allele",3,"mbd5-wt-allele",{"biomarker":344,"count":341,"slug":345},"X-linked Lymphoproliferative Syndrome 1","x-linked-lymphoproliferative-syndrome-1",[347,351,354,358,362,365,369,373,377,381,385,389,393,397,400,403,406,409,412,415,418,422,425,429],{"state":348,"count":349,"slug":350},"California",63,"california",{"state":352,"count":349,"slug":353},"Texas","texas",{"state":355,"count":356,"slug":357},"New York",59,"new-york",{"state":359,"count":360,"slug":361},"Florida",45,"florida",{"state":363,"count":360,"slug":364},"Ohio","ohio",{"state":366,"count":367,"slug":368},"Pennsylvania",35,"pennsylvania",{"state":370,"count":371,"slug":372},"North Carolina",34,"north-carolina",{"state":374,"count":375,"slug":376},"Washington",32,"washington",{"state":378,"count":379,"slug":380},"Tennessee",29,"tennessee",{"state":382,"count":383,"slug":384},"Illinois",26,"illinois",{"state":386,"count":387,"slug":388},"Michigan",25,"michigan",{"state":390,"count":391,"slug":392},"Wisconsin",24,"wisconsin",{"state":394,"count":395,"slug":396},"Maryland",23,"maryland",{"state":398,"count":395,"slug":399},"Massachusetts","massachusetts",{"state":401,"count":395,"slug":402},"Utah","utah",{"state":404,"count":395,"slug":405},"Virginia","virginia",{"state":407,"count":314,"slug":408},"Colorado","colorado",{"state":410,"count":314,"slug":411},"Georgia","georgia",{"state":413,"count":314,"slug":414},"Kentucky","kentucky",{"state":416,"count":314,"slug":417},"New Jersey","new-jersey",{"state":419,"count":420,"slug":421},"Minnesota",20,"minnesota",{"state":423,"count":420,"slug":424},"Oregon","oregon",{"state":426,"count":427,"slug":428},"Arizona",19,"arizona",{"state":430,"count":431,"slug":432},"Missouri",16,"missouri"]